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Introduction
Status epilepticus (SE) is a major neurological and medi-
cal emergency that is commonly expressed by a brain injury 
or systemic changes that lead to cerebral hyperexcitability. 
The incidence accounts for 61 episodes per 100000 per year, 
with a total mortality of approximately 20% (range 1.9-40%) 
[1, 2]. The reported incidence varies considerably depend-
ing on the used definition of SE. In addition, the incidence 
refers to episodes of clinically apparent SE, which do not 
incorporate the underestimated incidence of nonconvulsive 
SE. Multiple publications are controversial, with a partial 
approach to evolution, diagnostic and management crite-
ria. However, there has been considerable development in 
recent years in understanding the pathophysiology, causes, 
clinical features, changes in EEG, its prognosis and treat-
ment [3, 4]. 
Classically, it was defined as a “situation characterized 
by epileptic seizures long enough or repeated at short in-
tervals to produce a long-lasting epileptic disorder” [5]. 
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Abstract
Background: Status epilepticus (SE) is a major medical emergency and requires not only an emergency symptomatic treatment with antiepileptic drugs 
(AED) but also a rapid identification and treatment of the underlying cause. This narrative review summarizes the most important advances in SE 
classification and treatment. Data sources included being PubMed / Medline, and tracking references of the relevant studies, reviews and books. SE is 
now defined as “a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, 
which lead to abnormally prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), 
including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures.” The most effective acute 
treatments for early SE  are the intravenous benzodiazepines (lorazepam, diazepam, and clonazepam) and intramuscular midazolam. In children, oral or 
intranasal midazolam are useful alternatives. The intravenous antiepileptic drugs (phenytoin, valproate, levetiracetam, phenobarbital and lacosamide) 
are administered in confirmed SE. Treatment options in refractory SE are intravenous anesthetics; ketamine, magnesium, steroids and other drugs are 
used in super-refractory SE , showing variable results and outcomes.
Conclusions: Over time, major progress has been made in defining, classifying, and understanding of SE mechanisms. Despite this, the first-line drug 
management is ineffective in up to 40% of patients with SE. The super-refractory SE treatment is still unknown and no evidence-based data have been 
found yet. Thus, SE treatment strategies vary substantially from one institution to another due to the lack of data supporting a specific treatment plan.
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Initially, the proposed times ranged from 60 to 30 minutes. 
However, in terms of the operational definitions, clinicians 
do not wait for diagnosis confirmation and treatment, since 
the SE prognosis might worsen over time [6]. This issue has 
led to a more detailed operational definition [7]: a gener-
alized convulsive SE in adults and children over 5 years of 
age is defined as “a continuous seizure lasting ≥5 min or 
one or 2 seizures or even more might exhibit an incom-
plete recovery of consciousness between them”. This time 
interval was in general accepted by the medical community 
and used to guide the emergency treatment of generalized 
convulsive SE. However, other forms of SE were not con-
sidered until the last definition, being proposed in 2015 by 
the SE Working Group of the International League against 
Epilepsy (ILAE) [8]. 
According to the new definition approved in 2015, the 
SE is a condition resulting either from the failure of the 
mechanisms responsible for seizure termination or from 
the initiation of mechanisms, which lead to abnormally 
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prolonged seizures (after the time point t1) and which can 
have long-term consequences (after time point t2), includ-
ing neuronal death, neural injury, and alteration of neural 
networks, depending on type and duration of seizures [3, 8]. 
This definition is conceptual, with two operational dimen-
sions: the first is the duration of the seizure and time point 
(t1, at 5 min), above which the seizure should be considered 
as “continuous ictal activity”. The second time point (t2, at 
30 min) is the time followed by the risk of long-term conse-
quences [3, 8].
This new definition of SE provides good guidance when 
the emergency treatment needs to be considered. In general, 
the time point t1 is the time when treatment should be start-
ed, which is within 5 minutes, for generalized tonic-clonic 
seizures, and over 10 minutes, for focal seizures with or 
without an altered consciousness. Time point t2 highlights 
the time when the neuronal damage occurs or self-perpetu-
ation of alteration of neural networks starts, thus indicating 
that SE should be controlled as quickly as possible; 30 min, 
in case of generalized tonic-clonic seizures [3, 6]. The pro-
posed time points are based on clinical trials performed on 
animal models, as well as on  clinical researches. These data 
might vary, thus these specific moments should be consid-
ered as the best estimates available now. However, there are 
no data that have correctly defined all forms of SE , thus the 
study of these subtypes will allow their incorporation into 
the definition without changing the basic concept [6]. 
SE can be considered as the second most common acute 
neurological emergency after stroke. SE makes up 3.5% of 
total hospital admissions in developed countries and 11% 
within the developing countries [9, 10]. Nonconvulsive sta-
tus epilepticus (NCSE) accounts for approximately 1/3 of all 
SE cases. Compared to convulsive SE, NCSE has been given 
less attention, is underdiagnosed and undertreated. NCSE 
comprises a group of syndromes that have a great diversity 
in terms of response to anticonvulsant drugs, from practi-
cally self-limiting variants to completely refractory forms. 
The etiology and clinical form of NCSE are strong predic-
tors for the overall prognosis [11]. 
Status epilepticus classification
The ILAE working group also came up with a new classi-
fication that will provide a framework for clinical diagnosis, 
investigation, and therapeutic approaches for each patient, 
based on four axes. [3, 8]: (I) semiology, (II) etiology, (III) 
EEG correlations, and (IV) age. Semiology is thought to be 
the backbone of this classification. Different clinical forms 
of SE are differentiated based on two taxonomic criteria: 
the presence of motor activity and impaired consciousness 
falling into two major groups: SE with prominent motor 
symptoms, including all convulsive seizures, and SE without 
prominent motor symptoms that represent the underlying 
forms of NCSE (see Table 1).
Axis 1 (semiology) includes different forms of SE, being 
divided into those with prominent motor manifestations, 
those without prominent motor manifestations, as well as 
conditions not determined so far (such as acute confusional 
states with epileptiform patterns at EEG) [8]. Each group 
can be divided again, depending on the degree of the im-
paired consciousness, which is extremely clinically relevant. 
NCSE with coma is a life-threatening condition that requires 
urgent and consistent treatment, while NCSE without coma 
commonly occurs in the form of absence SE or focal status 
with impaired consciousness (the previous terms for these 
conditions were the “psychomotor status” or “partially com-
plex epileptic status”) [3, 8, 12]. 
Axis 2 (etiology) is divided into two groups: (i) known 
or symptomatic and (ii) unknown or cryptogenic. The 
symptomatic group can be subdivided into acute symptom-
atic, remote symptomatic and progressive symptomatic [3, 
6]. SE frequently occurs in the context of genetic epileptic 
syndromes, however, there are some triggers for the status 
itself, such as fever, electrolyte disturbances, or other intrin-
sic factors [13]. 
Axis 3 of classification includes EEG correlations. In 
convulsive SE, the clinical presentation is most often clear 
and with unclear artifacts on EEG, thus the EEG has a  low 
significance.  The non-convulsive SE otherwise cannot be 
often correctly diagnosed without an EEG. In most severe 
cases of patients with deep coma, only an EEG can reveal 
the epileptiform or rhythmic discharges that lead to the di-
agnosis [12, 14]. 
Table 1
Axis 1 of the classification of SE – semiology [3, 8]
(A) with prominent motor signs
1. Convulsive SE (CSE, synonym: tonic-clonic SE)
a. Generalized convulsive
b. Focal onset evolving into bilateral convulsive SE
c. Unknown whether focal or generalized
2. Myoclonic SE (with prominent epileptic myoclonic jerks)
a. With coma
b. Without coma
3. Focal motor
a. Repeated focal motor seizures (Jacksonian)
b. Epilepsia partialis continua (EPC) 
c. Adversive status
d. Oculoclonic status
e. Ictal paresis (i.e., focal inhibitory SE) 
4. Tonic status
5. Hyperkinetic SE
(B) Without prominent motor symptoms (i.e., NCSE)
1. NCSE with coma (including so-called “subtle” SE)
2. NCSE without coma
a. Generalized
i. Typical absence status
ii. Atypical absence status
iii. Myoclonic absence status
b. Focal 
i. Without impairment of consciousness (aura continua, with 
autonomic, sensory, visual, olfactory, gustatory, emotional/
psychic/experiential, or auditory symptoms) 
ii. Aphasic status
iii. With impaired consciousness 
c. Unknown whether focal or generalized
i. Autonomic SE
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Finally, the age should be considered, given that the eti-
ologies are different and there are some age-specific elec-
troclinical syndromes: newborn (<30 days), early childhood 
(1 month to 2 years), childhood (2–12 years), adolescence-
adult (12–59 years), and old age (> 60 years) [3, 6].
Status epilepticus – pathophysiology
The basic SE generating processes can be considered as 
failure of the normal mechanisms responsible for cessation 
of the seizures. Reduced inhibition and persistent excessive 
excitation might produce and sustain further epileptic ac-
tivity. During a prolonged seizure activity, dynamic changes 
in gamma-aminobutyric acid A (GABAA) and N-methyl-
D-aspartate (NMDA) receptors are observed, these have 
been termed as “receptor trafficking” [15]. During the ex-
cessive neuronal discharges, there is a gradual reduction of 
GABA-A receptors on the surface of the synaptic membrane 
with the internalization of receptors in the endocytic vesi-
cles and its subsequent degradation. This process induces 
the loss of endogenous GABA-ergic inhibition mediator 
giving rise to sustained epileptic activity [15-17]. The loss of 
post-synaptic GABA-A receptors is a relevant pathophysi-
ological factor for the onset of progressive drug resistance 
to drugs, such as benzodiazepines, barbiturates and propo-
fol [18]. In contrast, in continuous epileptic activity, NMDA 
receptors are progressively transported to the surface of the 
synaptic membrane, resulting in an increase in the number 
of excitatory NMDA receptors in the synaptic cleft. This 
process facilitates neuronal excitability and SE continuity 
[15]. On the other hand, an increased expression of GABA 
receptors may be a useful target  for pharmacological man-
agement in advanced stages of SE [18]. Absence SE and 3 Hz 
slow spike-wave discharges are induced by excessive inhibi-
tion. This form of SE does not lead to significant neuronal 
damage.
Brain damage in Status epilepticus
The severity of cerebral hypoxia during convulsive SE 
is unlikely to cause brain damage [18, 19], though it may 
trigger some other factors that impair the brain function-
ing, such as hyperthermia, hypotension, hypoglycemia, and 
acidosis [19]. These factors are particularly relevant after 
the compensatory mechanisms have failed [18, 19]. In non-
human primates, prolonged seizures lead to lesions in the 
cortex, cerebellum and hippocampus with a pattern similar 
to that seen in circulatory arrest, systemic hypotension or 
hypoglycaemia [18]. A characteristic neuropathology that 
has been associated with prolonged convulsive SE is hippo-
campal sclerosis which consists of a loss of neurons in the 
dentate nucleus and pyramidal layer of the hippocampus 
with variable gliosis [20].  
In 1880, Sommer was the first to describe in detail the 
hippocampal sclerosis in the brains of epileptic patients [21]. 
Since then, the controversy over hippocampal sclerosis is 
considered both a cause and a consequence of SE, which sup-
port the existing hypotheses [22]. While the relationship of 
prolonged seizures to hippocampal sclerosis has well been es-
tablished in animal models, there is no strong  evidence that 
SE causes hippocampal sclerosis in humans [23]. Therefore, 
it is likely that hippocampal sclerosis might be both the cause 
and the consequence of convulsive SE, showing a varied pre-
dominance in different clinical scenarios [20].  
Although most of the specialized literature on the neu-
ropathology of brain lesions in SE refers to seizures, there is 
evidence that non-seizures also might cause brain damage. 
When prolonged seizures are induced in paralyzed and ar-
tificially ventilated non-human primates, the neuronal in-
jury is less severe, especially in cerebellum. Epileptic activity 
alone leads to neuronal damage and neuronal death, mainly 
due to excessive activation of glutamate receptors and sub-
sequent influx of Ca2 + into the neuron [24]. Although the 
epileptic mechanisms are fully understood in animals, the 
additional impact over the etiology in humans is still un-
certain.
Status epilepticus diagnosis 
The diagnosis of SE is based on the EEG. The record-
ing of epileptiform changes, which correspond to the motor 
clinical manifestations in convulsive SE is the main diagnos-
tic criteria in this clinical form [25]. Moreover, if the diagno-
sis of convulsive SE is usually not difficult to confirm, then 
in nonconvulsive SE the EEG has a decisive role, whereas 
the lack of motor clinical manifestations is the main impedi-
ment in this regard. Over the years, a number of researches 
have been published that have tried to standardize and de-
velop the criteria for diagnosing NCSE [26-28]. 
The ILAE Working Group recommends describing EEG 
correlations in a SE patient by using the following descrip-
tors: paternal name, morphology, location, time-related 
characteristics, modulation, and effect of intervention, as 
well as by using the terminology recently proposed by the 
Table 2
Salzburg EEg criteria for nCSE [29-31]
Patients without known epileptic encephalopathy: 
EDs > 2.5 Hz, or
EDs ≤ 2.5 Hz or rhythmic delta/theta activity (>0.5 Hz) and one of 
the following:  
EEG and clinical improvement after intravenous AED*, or  
Subtle clinical ictal phenomena during the EEG patterns men-
tioned above, or
Typical spatiotemporal evolution**
Patients with known epileptic encephalopathy:
Increase in prominence or frequency of the features mentioned 
above, when compared to baseline with observable change in 
clinical state
Improvement of clinical and EEG features with intravenous AEDs   
*If EEG improvement occurs without clinical improvement, or if 
fluctuation is without definite evolution, this should be considered 
possible NCSE.
** Incrementing onset (increase in voltage and change in frequency), or 
evolution in pattern (change in frequency >1 Hz or change in location), 
or decrementing termination (voltage or frequency).
EDs, epileptiform discharges (spikes, poly spikes, sharp-waves, sharp-and-
slow-wave complexes); AEDs: antiepileptic drugs.
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American Clinical Neurophysiology Society and “Salzburg 
EEG criteria for NCSE” (Table 2) [14, 29-32], as a practical 
diagnostic guide. Thus, based on the peculiarities of EEG, 
the researchers proposed to develop a diagnostic decision, 
based on the NCSE type (electroclinical classification) and 
the presumed etiological factor [33]. Subsequently, a reduc-
tion in the rate of false diagnosis of NCSE was reported due 
to the implementation of this score [31]. Therefore , diffe-
rent EEG patterns in coma and the diagnosis of NCSE in 
these cases  were difficult to differentiate for a while, how-
ever, this dilemma was solved later [14]. Conventional and 
quantitative methods in the diagnosis of major emergency 
cases have also been studied and proposed [34]. However, 
according to Lettinger’s data [35], the so-called Salzburg cri-
teria for diagnosing NCSE, proposed by Beniczky and his 
workteam [33], show a sensitivity of 75% in short recordings 
up to 97.7 % in long-term EEG recordings (up to 74 hours), 
with a specificity of 89.6% [35] and are an important tool in 
diagnostic and therapeutic decisions in these patients.
Status epilepticus treatment
The management of SE and its pharmacological treat-
ment is another area of limited evidence derived from high-
quality randomized controlled trials, appropriately selected 
to inform clinical practice. However, there has been clear 
progress in understanding the pathomechanisms, which 
have led to more effective treatment strategies [3]. The 
therapeutic principle “Time is the brain” might be applied 
not only to stroke, but also to SE, since the prognosis of 
SE worsens with the duration of increasing convulsive ac-
tivity [36, 37]. Indeed, prompt SE confirmation and early 
treatment is associated with lower morbidity and mortality, 
fewer drugs required for inpatients, and a decreased seizure 
duration [38]. Fortunately, SE responds to relatively simple 
treatment, but when simple interventions fail, refractory 
SE requires a more aggressive treatment to prevent compli-
cations. However, there is a limited interest in the indus-
try to develop new treatments to prevent refractory status. 
However, the latest ILAE definition has led to standard ac-
tion protocols, which have been adapted to time points t1 
and t2 [6]. 
The most recent reviews focus on SE pharmacotherapy, 
but the general measures of any neurological emergency are 
just as important (airway maintenance, oxygen therapy SaO2 
> 95%, stabilization of vital signs: blood pressure, tempera-
ture, and glycemia). Other measures include intravenous 
glucose and thiamine as required, emergency measurement 
of antiepileptic drugs, electrolytes, and magnesium, a com-
plete haematological screening and liver and kidney func-
tion [39, 40]. In addition, it is essential to carry out a tho-
rough search of the simultaneous etiology, because an early 
etiological treatment is highly important for the subsequent 
prognosis [3, 6, 39]. 
The main purpose of treatment is to immediately stop 
both clinical convulsive activity and electrographic ictal 
activity. The initial treatment strategy includes simultane-
ous assessment and management of the airways, respiration 
rate and circulation (aimed to provide intravenous access, 
O2administration, and airway safety as needed), immedi-
ate treatment with AED drugs (benzodiazepines), screen-
ing for the main cause of SE, and immediate treatment of 
life-threatening causes of SE (e.g. meningitis, intracranial 
mass injury) [39, 40]. Once SE is under control and the vi-
tal signs are stable, specific diagnostic examinations should 
be performed. These diagnostic investigations are selected 
based on the patient’s medical history and physical exami-
nation. Not every diagnostic test is necessary for every pa-
tient. For example, a lumbar puncture is generally necessary 
if there is any suspicion of central nervous system infection 
but may be unnecessary in suspected meningitis, especially 
in patients with AED noncompliance [39]. If the patient is 
currently being treated with antiepileptic drugs (AED), the 
serum AED levels should be checked, and compliance his-
tory should be obtained. A comprehensive toxicology pro-
file should be performed if there is no clear etiology for SE. 
Specific toxicological testing should be carried out if history 
or physical examination suggests a specific toxin. 
By the late 1980s there were large variations in patient 
stabilization procedures, laboratory measures, and the 
sequence of drugs in SE management [41]. In 1993, the 
Epilepsy Foundation of America organized a working group 
on SE. They published guidelines and a treatment protocol 
[42], which was based on the literature and expert opinions. 
Some of the key treatment principles included within this 
guide are still valid. All treatment protocols recognize a step-
by-step approach to treatment with different drugs used in 
early SE (stage I), established SE (stage II), refractory (stage 
III) and super-refractory SE (stage IV) and underline the 
recognition and prompt treatment of persistent convulsive 
activity at each stage in order to reduce morbidity, morta-
lity and long-term consequences of SE (other than t2) [39, 
43].  Therefore, these guidelines have revised the traditional 
SE treatment paradigm to initial emergency therapy, emer-
gency control therapy and refractory SE therapy. Patients 
with refractory SE who do not respond to initial therapy and 
super-refractory SE should be treated in highly experienced 
centers. All patients with SE will need initial AED emerging 
therapy (i.e., first line) and emergency control AED ther-
apy (i.e., line 2), in addition to AED maintenance therapy, 
even if SE has been controlled immediately. According to 
the definition, refractory SE therapy (i.e. 3rd and 4th line) 
is administered for those who do not respond to the first 2 
antiepileptic drugs.
If the SE is caused by a metabolic disorder (e.g. hypo-
glycaemia), the underlying metabolic disorder must be cor-
rected, thus the maintenance therapy may not require. It 
must be considered that, although the treatment includes 
a series of stages, the treatment itself is an ongoing process, 
thus the urgent cessation of convulsive activity is the major 
goal applied to each stage.
Most clinical trials were conducted in the early stages of 
SE, which was the subject of several trials and critical evalu-
ations in systematic reviews of meta-analyses [44-49] and 
included in treatment protocols or practical guidelines [39, 
43, 50, 51]. 
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Stage 1: early SE. Although several AEDs have been 
studied as first-line therapy for SE, the evidence and experts 
agree that benzodiazepines should be the drug of choice for 
initial treatment. Benzodiazepines can rapidly control SE in 
about two-thirds of patients [4, 48]. The most commonly 
first-line treatments are diazepam, midazolam and clona-
zepam (intravenous lorazepam is not marketed in our coun-
try). Although the controlled studies demonstrated the su-
periority of lorazepam [52, 53], a recent comparative meta-
analysis of 5 clinical trials found that there is no difference in 
efficacy or side effects between lorazepam and intravenous 
diazepam [54]. Benzodiazepines exert their antiepileptic 
properties by increasing inhibitory neurotransmission by 
increasing channel opening and GABA-A receptor frequen-
cy, with subsequent increase in chlorine conductance and 
neuronal hyperpolarization [55, 56]. This first-line treat-
ment should be used as early as possible before point  t1 
in the SE definition, which means it has a major role in the 
pre-hospital settings. In this context, the intravenous route 
may be difficult, and other routes of administration, such 
as intramuscular [38], intranasal or oral midazolam [57], 
have proven to be more  practical, faster and safer alterna-
tives. The  pre-hospital recognition of SE is easy to perforn 
in convulsive SE or that with motor involvement; however, 
the non-convulsive SE  may be more difficult to detect and 
treat, thus  clinical scores should be developed or devices 
should be  used to allow faster detection [6]. 
At the same time, supportive treatment should be pro-
vided, as rapid administration of benzodiazepines may 
cause respiratory depression and hypotension. Patients who 
have responded to initial emergency therapy and have a 
complete resolution of SE should continue dosing for main-
tenance therapy in order to rapidly achieve the therapeutic 
levels of AED. Urgent control therapy is to stop SE in pa-
tients who do not respond to initial emergency therapy. 
Stage 2: established SE. Approximately 40% of patients 
with generalized convulsive SE are refractory to benzodiaz-
epine treatment [53, 58]. This ongoing convulsive activity 
is called the established SE (or stage II). In established SE, 
intravenous antiepileptic drugs (phenytoin, valproic acid, 
levetiracetam, phenobarbital and lacosamide) are the most 
commonly used; however, there are no classes of evidence 
to choose between them. This unsatisfactory condition has 
several consequences: first of all, most patients are provided 
off-label treatment. 
A meta-analysis comparing the first 4 drugs resulted 
in higher rates of cessation of seizures with valproic acid 
(75.7%, 95% CI: 63.7–84.8) and phenobarbital (73.6%; 95% 
CI: 58.3–84.8) than with levetiracetam (68.5%; 95% CI: 
56.2–78.7) or phenytoin (50.2%; 95% CI: 34.2–66.1). Based 
on this and the favorable tolerability profile of levetiracetam 
and valproic acid, the authors prefered these drugs to phe-
nytoin / phosphenytoin in established SE [59]. 
In patients with known epilepsy who have been on an 
AED prior to admission, case-by-case intravenous bolus ad-
ministration of AED was given, if available, prior to initia-
tion of an additional agent. This may also include additional 
boluses to achieve higher-than-normal target concentra-
tions of AED to achieve the desired therapeutic response 
(i.e., cessation of seizure activity).
Currently, a large multicenter, randomized, blinded 
study is being conducted, funded by the National Institute 
of Health (Established Status Epilepticus Trial), which 
compares the efficacy of phosphenytoin, valproic acid or 
levetiracetam in the treatment of patients with benzodiaze-
pine-refractory SE [60]. Unless the results of this study are 
avai-lable, other drugs, such as lacosamide, are also widely 
used in established and refractory SE, which have been re-
cently reviewed and published [61]. In any case, it is about 
prioritizing drugs with better tolerance, easy to administer 
and with few pharmacological interactions (levetiracetam 
and lacosamide).
It is important to use the correct doses at this stage, as 
one of the recognized problems for non-response is the use 
of subtherapeutic AED doses [62]. The recommended doses 
are presented in table 3.
Table 3
Different doses of drugs used in the second –  
and third-line-treatment
Drug Dose
Second-line treat-
ment (AED)
Valproic acid
Phenobarbital
Phenytoin
Lacosamide
Levetiracetam
Third-line treat-
ment (anaesthetics)
Propofol
Midazolam
Ketamine 
Thiopental
30 (20–40) mg/kg on 5–10 min
10–20 mg/kg in 15–20 min
15–20 mg/kg. infusion <50 mg/min
5–6 mg/kg in 10–15 min
60 (30–60) mg/kg, max.4500 mg, in 5–10 min 
Bolus 2 mg/kg; infusion 2–10 mg/kg/h
Bolus 0.1–0.3 mg/kg at −4 mg/min; infusion 
0.05–2 mg/kg/h
Bolus: 0.5–3 mg/kg; infusion 1 mg/kg/h – of 
10 mg/kg/h
Bolus: 3–5 mg/kg in 3–5 min; repeat bolus 
1–2 mg/kg; after 3 min perfusion: 
3–7 mg/kg/h
AEDs – antiepileptic drugs, h – hour, kg – kilogram, mg – milligrams.
Regarding lacosamide, a weight-adjusted dose was not 
considered until recently [63]. 
Stage 3: refractory SE. 31-43% of patients with es-
tablished SE seizures are not controlled with antiepileptic 
drugs [64-66]. In most cases, continuous EEG and / or clini-
cal examination will determine the persistence of SE after 
initial AED treatment. Refractory SE is considered when 
two treatment lines have failed (one of which is benzodiaz-
epines) at appropriate doses. Refractory cases are associated 
with mortality and therefore there is consensus in recom-
mending the use of intravenous anesthetics (midazolam, 
propofol or barbiturates) as the next line of treatment to 
control ictal activity. However, there are no data from ran-
domized trials to support the recommended anesthetic, 
thus medications should be used, based on the experience 
of each separate hospital.
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There is no consensus on achieving optimal sedation 
(only ictal activity suppression, burst-suppression pattern 
or isoelectric pattern). Each anesthetic option has its own 
considerations (doses are shown in Table 3). 
– Propofol may be associated with metabolic acidosis, 
rhabdomyolysis, renal failure and heart failure. The propo-
fol infusion syndrome is less likely to be treated for less than 
48 hours and not more than 5 mg / kg / h.
– Midazolam seems the safest drug at this stage, with the 
lowest rate of metabolic complications [67, 68]. 
– Barbiturates are frequently associated with cardiovas-
cular complications, severe immunosuppression, and infec-
tions.
In a worldwide research study of 488 episodes of refrac-
tory SE, a continuous infusion of midazolam was the most 
widely used anesthetic (59%), followed by propofol (32%) 
and barbiturates (8%) [69]. The ongoing use of infusion 
AEDs often requires assisted ventilation and cardiovascular 
monitoring. Vasopressor agents may be needed due to hy-
potension and cardiopulmonary depression related to these 
agents. Once the sedation is discontinued, the dose is rec-
ommended to be gradually reduced over 24 hours if no ictal 
activity occurs, over 12 hours in case of barbiturates, as well 
as gradually reduced over the next 12 hours and 24 hours in 
case of midazolam or propofol.
Another anesthetic that has regained interest is ket-
amine. It has a significant antagonistic effect on N-methyl-
D-aspartate glutamate receptors, which play a key role in 
the advanced stages of SE [70]. Ketamine is a racemic 
mixture that contains equal amounts of two enantio-
mers, (S)- and (R)-ketamine. Ketamine is metabolized by 
N-demethylation to produce norketamine, a non-compet-
itive NMDA receptor antagonist that may also exhibit en-
antioselective pharmacological activity. (S)-ketamine has 
different pharmacodynamic activities and is two to three 
times stronger as an analgesic agent than (R)-ketamine. (S)-
ketamine administered alone has a higher clearance than in 
the racemic mixture resulting in rapid elimination, shorter 
duration of action and faster recovery from anesthesia [71]. 
There are several series and isolated cases that report an ef-
ficiency in refractory SE of about 63%, and in particular it 
seems that the form (S)-ketamine has advantages in terms 
of better psychomotor recovery than the racemic form [72]. 
The problem, apart from the lack of clinical data, is that 
various observational studies have recently shown that the 
use of anesthetics has been associated with a worse progno-
sis of SE, in addition to the increase in hospital stay, which 
leads to some concern about to the safety of the use of in-
travenous anesthetics in the refractory SE approach [73, 
74]. For this reason, an individualized approach to sedation 
should be applied, in case if the ictal activity can leave per-
manent sequelae (t2) or depending on the type of SE.
There are no data to guide the transition from continu-
ous infusion therapy to intermittent maintenance therapy 
after resolution of refractory SE. The overall maintenance 
drugs are given in sufficient doses to maintain therapeutic 
concentrations during and after the continuous infusion is 
discontinued. Therapeutic concentrations may exceed tar-
get concentrations for several antiepileptic drugs and dos-
age should be individualized to control seizures and mini-
mize side effects. The success of the maintenance regimen is 
predicted by many clinical features, including EEG pattern, 
cause of SE, concurrent systemic disease, and drug-drug in-
teraction profiles.
The most recent AEDs that have started to be used in 
this refractory phase of SE are the following:
Lacosamide. The use of lacosamide is based on clinical 
experience. A review of all 522 SE series cases (486 adults 
and 36 children) has recently been published, showing an 
overall efficiency of 57%. The efficacy is the same for both 
non-convulsive SE and  convulsive SE, being higher than in 
previously used ones [61]. Although its use was first imple-
mented in the refractory phase, it has been updated as the 
first- or second-line treatment option after benzodiazepines 
in many healthcare centers due to  its speed of action and 
few side effects.
Perampanel. It exerts its mechanism in the antiglutama-
tergic pathway, through AMPA receptors. Unlike ketamine 
it does not act, even at high doses on NMDA receptors, but 
it is an uncompetitive antagonist of the alpha-amino-3-hy-
droxy-5-methyl-4-isoxazole-propionic acid (AMPA) recep-
tor [75]. Although the intravenous formula has not been 
marketed yet, its use via the nasogastric tube has been re-
ported in limited cases of SE, with doses ranging between 4 
and 32 mg [6, 64, 76]. The number of patients in these series 
of cases was quite small (the largest single-center experience 
with 12 cases), while the patients were too heterogeneous to 
draw valid conclusions about its efficacy.
Brivaracetam. It is available on the market as intrave-
nous form and therefore considered potentially usable in 
SE.  To date, only 2 series have been published with a total of 
17 patients, showing a variable efficacy [77, 78]. 
Stage 4: Super-refractory SE. Super-refractory SE is 
considered when SE continues, even though the anesthetic 
treatment has been initiated in high doses or when it re-
sumes within the first 24 hours after the anesthetic with-
drawal. At this stage, there are no data from clinical trials 
that have shown effective treatment and several options are 
described [68, 79], some of which have been published as 
isolated clinical cases.
Pharmacological therapies:
•	Intravenous	 anesthetics	 (thiopental	 /	 pentobarbital,	
midazolam, propofol, and ketamine). It is usually the 
first-line option administered in SE patients to restart 
or increase sedation again.
•	Inhalation	anesthetics.
•	Other	AEDs:	topiramate,	lacosamide,	pregabalin,	leve-
tiracetam and brivaracetam.
•	Magnesium	sulphate.
•	Pyridoxine.
•	Immunotherapy.
•	Neurosteroids.
Non-pharmacological therapies:
•	Hypothermia.
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•		Ketogenic	diet.
•	Surgery.
•	Electroconvulsive	therapy.
•	Drainage	of	the	cerebrospinal	fluid.
•	Repetitive	magnetic	stimulation.
•	Vagus	nerve	stimulation.
•	Deep	brain	stimulation.
As regarding the immunotherapy, there is a growing 
evidence of the role of inflammation in some refractory 
SEs, as well as in epileptogenesis [80]. In addition, antibod-
ies against neuronal components are more commonly de-
scribed as the cause of encephalopathy with seizure and re-
fractory and super-refractory SE [81]. In addition, final re-
sults of complementary examinations that have confirmed 
an autoimmune cause might take weeks in these cases and 
in these serious conditions, especially in newly-onset SE 
(NORSE, New-Onset Refractory Status Epilepticus). Thus, 
various studies explain that early use can be beneficial to 
avoid serious consequences [82, 83]. Therefore, immuno-
therapy, including glucocorticoids, immunoglobulins, and 
plasmapheresis, might be an option in various guidelines in 
the super-refractory phase [39]. 
On the other hand, glucocorticoids may have additional 
non-immunological effects, such as changes in the open-
ing of the blood-brain barrier essential for the persistence 
of epileptic activity and may reverse GABAergic inhibi-
tion, in addition to their effects on intracranial pressure 
[79]. However, when testing these therapies, potential side 
effects, such as severe infections or metabolic disorders 
should be considered.
Recently, the potential use of neurosteroids (brexano-
lone) has been described in super-refractory phase. Despite 
the name, these are not anti-inflammatory treatments, but 
they modulate the synaptic and extrasinaptic gamma-ami-
nobutyric type A (GABA-A) receptors (synaptic receptors 
are internalized in the cell during the super-refractory SE 
phase, that is  why benzodiazepines do not respond ; they 
only bind to the synaptic ones) [84]. 
Conclusions
Major clinical advances have been made, regarding the 
new definition and classification of SE, thus providing the 
clinicians with better guidance on the time of treatment 
initiation, aggressiveness of treatment, and how to avoid 
over- or under-treatment of this condition. Furthermore, 
new small pharmaceutical companies are involved in the 
development of niche products, such as neurosteroids in 
super-refractory SE or new alternative routes of administra-
tion. An increased interest among physicians regarding SE 
has alerted them to provide an early and more appropriate 
treatment, as well as to determine the causes of SE in each 
individual patient.
Despite these progresses, there are still many issues to 
solve, starting with identifying the cause-oriented treatment 
not only to prevent the SE recurrence, but also to protect the 
brain from the SE impact and the development of epilepsy, 
as well as better distinguish the status subtypes. This might 
be achieved only by a better understanding of the mecha-
nisms of various SE etiology, as well as by reducing the gap 
between the preclinical knowledge used in treatment of hu-
mans.
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